Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 May 25;11(6):e01167.
doi: 10.1002/rcr2.1167. eCollection 2023 Jun.

Rapid onset of effect of benralizumab in a severe eosinophilic and allergic asthma patient with allergic bronchopulmonary aspergillosis

Arvindran Alaga  1 , Khairil Ashraff  1 , Nurul Hana Din Khan  1
Affiliations
Case Reports

Rapid onset of effect of benralizumab in a severe eosinophilic and allergic asthma patient with allergic bronchopulmonary aspergillosis

Arvindran Alaga et al. Respirol Case Rep. .

Abstract

There is limited data on the use of benralizumab in patients with severe asthma, who have allergic bronchopulmonary aspergillosis (ABPA). We report the case of a 65-year-old woman with combined severe eosinophilic and allergic asthma, who presented with refractory respiratory symptoms, hypereosinophilia and high immunoglobulin E (IgE) level. The patient had consistently poor Asthma Control Test (ACT) scores, despite a maximum dose of inhalation therapy. Upon further investigations, she was diagnosed with concomitant ABPA. The patient was started on oral prednisolone and itraconazole, but her symptoms persisted. She was then started on subcutaneous omalizumab, but switched to benralizumab after developing a severe allergic reaction. The patient experienced rapid clinical improvements after the first dose of subcutaneous benralizumab. Benralizumab demonstrated a significant role in reducing the exacerbation rate and oral corticosteroid use in this patient, as well as improving lung function, asthma control, and quality of life measures.

Keywords: allergic asthma; allergic bronchopulmonary aspergillosis; benralizumab; case report; eosinophilic asthma.

PubMed Disclaimer

Conflict of interest statement

Arvindran Alaga, Khairil Ashraff, and Nurul Hana Din Khan declare no conflict of interest.

Figures

FIGURE 1
FIGURE 1
Computed tomography (CT) scan of the thorax, depicting central bronchiectasis due to allergic bronchopulmonary aspergillosis (ABPA).
FIGURE 2
FIGURE 2
Spirometry with bronchodilator (A) pre‐ and (B) post‐benralizumab.
See this image and copyright information in PMC

References

    1. Pelaia C, Crimi C, Benfante A, Caiaffa MF, Calabrese C, Carpagnano GE, et al. Therapeutic effects of benralizumab assessed in patients with severe eosinophilic asthma: real‐life evaluation correlated with allergic and non‐allergic phenotype expression. J Asthma Allergy. 2021;14:163–73. - PMC - PubMed
    1. Agarwal R, Chakrabarti A, Shah A, Gupta D, Meis JF, Guleria R, et al. Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy. 2013;43(8):850–73. - PubMed
    1. Jack J, Bajaj T. Allergic bronchopulmonary aspergillosis. [Updated 2022 Aug 8]. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. https://www.ncbi.nlm.nih.gov/books/NBK542329/ Accessed December 23, 2022. - PubMed
    1. Agarwal R, Aggarwal AN, Gupta D, Jindal SK. Aspergillus hypersensitivity and allergic bronchopulmonary aspergillosis in patients with bronchial asthma: systematic review and meta‐analysis. Int J Tuberc Lung Dis. 2009;13(8):936–44. - PubMed
    1. Agarwal R, Sehgal IS, Dhooria S, Aggarwal AN. Developments in the diagnosis and treatment of allergic bronchopulmonary aspergillosis. Expert Rev Respir Med. 2016;10(12):1317–34. - PubMed

Publication types

LinkOut - more resources